New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

Author： van de Donk Niels WCJ   Lokhorst Henk M  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.12, 2013-08, pp. : 1569-1573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions

By Offidani Massimo   Corvatta Laura   Morabito Fortunato   Gentile Massimo   Musto Pellegrino   Leoni Pietro   Palumbo Antonio  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 779-793

Informa Healthcare

Access to resources Recommend Favorite

Carfilzomib: In Relapsed, or Relapsed and Refractory, Multiple Myeloma

By McCormack Paul L.  

Drugs, Vol. 72, Iss. 15, 2012-10 ,pp. : 2023-2032

Adis International

Access to resources Recommend Favorite

Lenalidomide: A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma

By Scott Lesley J.   Lyseng-Williamson Katherine A.  

Drugs, Vol. 71, Iss. 5, 2011-03 ,pp. : 625-649

Adis International

Access to resources Recommend Favorite

High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients

By Barbee Meagan S.   Nooka Ajay   Kaufman Jonathan L.   Kim Sungjin   Chen Zhengjia   Heffner Leonard T.   Lonial Sagar   Harvey R. Donald  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 853-862

Blackwell Publishing

Access to resources Recommend Favorite